Shares of Progyny, Inc. (NASDAQ:PGNY – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $33.9091.
Several research firms recently commented on PGNY. Leerink Partners set a $38.00 target price on Progyny in a report on Wednesday, July 22nd. Wells Fargo & Company initiated coverage on Progyny in a report on Thursday, August 20th. They set an “overweight” rating and a $37.00 price target for the company. Bank of America upped their price objective on Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Canaccord Genuity Group set a $35.00 price objective on Progyny in a report on Friday, August 7th. Finally, Weiss Ratings raised Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, August 13th.
View Our Latest Stock Report on Progyny
Progyny Price Performance
Progyny (NASDAQ:PGNY – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. During the same quarter last year, the company earned $0.19 earnings per share. The firm’s revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Analysts expect that Progyny will post 1.25 EPS for the current fiscal year.
Progyny declared that its Board of Directors has initiated a share buyback plan on Tuesday, May 26th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the company to repurchase up to 10.3% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.
Insider Activity at Progyny
In related news, EVP Allison Swartz sold 1,199 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $25.02, for a total value of $29,998.98. Following the transaction, the executive vice president directly owned 83,316 shares of the company’s stock, valued at $2,084,566.32. This trade represents a 1.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Mark S. Livingston sold 2,517 shares of Progyny stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $25.50, for a total transaction of $64,183.50. Following the sale, the chief financial officer owned 74,688 shares in the company, valued at $1,904,544. This represents a 3.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,315 shares of company stock worth $109,205 over the last quarter. 9.90% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Progyny
Several large investors have recently bought and sold shares of the stock. Easterly Investment Partners LLC increased its position in Progyny by 197.4% during the fourth quarter. Easterly Investment Partners LLC now owns 146,013 shares of the company’s stock worth $3,750,000 after buying an additional 96,912 shares during the period. First Eagle Investment Management LLC boosted its holdings in shares of Progyny by 40.2% in the fourth quarter. First Eagle Investment Management LLC now owns 212,612 shares of the company’s stock valued at $5,460,000 after acquiring an additional 60,912 shares during the period. Bank of America Corp DE boosted its holdings in shares of Progyny by 75.3% in the first quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock valued at $20,223,000 after acquiring an additional 511,609 shares during the period. CenterBook Partners LP grew its position in shares of Progyny by 36.2% during the fourth quarter. CenterBook Partners LP now owns 578,171 shares of the company’s stock worth $14,847,000 after acquiring an additional 153,778 shares during the last quarter. Finally, Simcoe Capital LLC purchased a new position in shares of Progyny during the fourth quarter worth approximately $3,902,000. Institutional investors and hedge funds own 94.93% of the company’s stock.
Progyny Company Profile
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Featured Stories
- Five stocks we like better than Progyny
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
